Prostate Cancer

Acapodene lowered LDL, raised HDL in prostate cancer patients on androgen deprivation therapy

Published in Cancer Weekly, July 18th, 2006

GTx, Inc., (GTXI), a men's health biotech company, announced the results of a lipid interim analysis of the pivotal phase III androgen deprivation therapy (ADT) clinical trial evaluating oral, once daily Acapodene (toremifene citrate) 80 mg for the treatment of the multiple serious side effects of androgen deprivation therapy in men with advanced prostate cancer.

The lipid interim analysis was performed in the first 197 subjects who completed 1 year of the trial. Prostate cancer patients on ADT who received Acapodene compared to placebo had lower total cholesterol (-7.1%; p=0.001), LDL (-9.0%; p=0.003), and triglyceride (-20.1%; p=0.009) levels, a reduction in the total...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-07-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry